The incidence rate of breast cancer for African American women has recently converged with that of non‐Hispanic White women in the United States, although African Americans have a higher mortality rate due to this disease. Although most research exploring health disparities associated with this phenomenon has focused on differences between women based on biology and behavior, both the academic and lay communities have begun to explore the potential role of environmental exposure to estrogen and endocrine disrupting chemicals (EDCs). This study reviews the current state of the science associating one such means of exposure, hair products containing EDCs, with breast cancer risk in African American women. We found a growing body of evidence linking: (1) environmental estrogen and EDC exposures to breast cancer risk, (2) the presence of such chemicals in personal care products, including hair products, and (3) the use of certain hair products with potential breast cancer risk in African Americans. At the same time, there is also increasing concern in the lay community about this risk. These results indicate the need for additional research, and the opportunity to benefit from strategic partnerships in community‐collaborative approaches in order to better understand the potential “cost of beauty.”
African American (AA)/Black men are more likely to develop aggressive prostate
cancer (PCa), yet less likely to be screened despite guidelines espousing shared
decision-making regarding PCa screening and prostate-specific antigen (PSA)
testing. Given the documented racial disparities in PCa incidence and mortality,
engaging interactions with physicians are especially important for AA/Black men.
Thus, this study evaluated occurrence of physician–patient conversations among
AA/Black men, and whether such conversations were associated with PCa knowledge.
We also quantified the serum PSA values of participants who had, and had not,
discussed testing with their physicians. Self-identified AA/Black men living in
California and New York, ages 21–85, donated blood and completed a comprehensive
sociodemographic and health survey (n = 414). Less than half
(45.2%) of participants had discussed PCa screening with their physicians.
Multivariate analyses were used to assess whether physician–patient
conversations predicted PCa knowledge after adjusting for key
sociodemographic/economic and health-care variables. Increased PCa knowledge was
correlated with younger age, higher income and education, and having discussed
the pros and cons of PCa testing with a physician. Serum PSA values were
measured by ELISA. Higher-than-normal PSA values were found in 38.5% of men who
had discussed PCa screening with a physician and 29.1% who had not discussed PCa
screening. Our results suggest that physician–AA/Black patient conversations
regarding PCa risk need improvement. Encouraging more effective communication
between physicians and AA/Black men concerning PCa screening and PSA testing has
the potential to reduce PCa health disparities.
Glucocorticoid receptor (GR) is emerging as a key driver of prostate cancer (PCa) progression and therapy resistance in the absence of androgen receptor (AR) signaling. Acting as a bypass mechanism, GR activates AR-regulated genes, although GR-target genes contributing to PCa therapy resistance remain to be identified. Emerging evidence also shows that African American (AA) men, who disproportionately develop aggressive PCa, have hypersensitive GR signaling linked to cumulative stressful life events. Using racially diverse PCa cell lines (MDA-PCa-2b, 22Rv1, PC3, and DU145) we examined the effects of glucocorticoids on the expression of two stress oncoproteins associated with PCa therapy resistance, Clusterin (CLU) and Lens Epithelium-Derived Growth Factor p75 (LEDGF/p75). We observed that glucocorticoids upregulated LEDGF/p75 and CLU in PCa cells. Blockade of GR activation abolished this upregulation. We also detected increased GR transcript expression in AA PCa tissues, compared to European American (EA) tissues, using Oncomine microarray datasets. These results demonstrate that glucocorticoids upregulate the therapy resistance-associated oncoproteins LEDGF/p75 and CLU, and suggest that this effect may be enhanced in AA PCa. This study provides an initial framework for understanding the contribution of glucocorticoid signaling to PCa health disparities.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations –citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.